enVVeno Medical Corporati... (NVNO)
NASDAQ: NVNO
· Real-Time Price · USD
0.96
0.01 (0.89%)
At close: Oct 03, 2025, 3:59 PM
0.96
0.18%
After-hours: Oct 03, 2025, 06:32 PM EDT
0.89% (1D)
| Bid | 0.94 |
| Market Cap | 18.48M |
| Revenue (ttm) | 812K |
| Net Income (ttm) | -23.07M |
| EPS (ttm) | -1.2 |
| PE Ratio (ttm) | -0.8 |
| Forward PE | -0.95 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 0.98 |
| Volume | 217,857 |
| Avg. Volume (20D) | 948,141 |
| Open | 0.96 |
| Previous Close | 0.95 |
| Day's Range | 0.94 - 0.98 |
| 52-Week Range | 0.67 - 5.62 |
| Beta | 0.94 |
| Ex-Dividend Date | n/a |
About NVNO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NVNO
Website n/a
1 month ago
-17.09%
EnVVeno Medical shares are trading lower after the...
Unlock content with
Pro Subscription
1 month ago
-72.08%
EnVVeno Medical shares are trading lower after the company announced the FDA has not approved its VenoValve PMA submission.
1 month ago · accessnewswire.com
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)IRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous diseas...
2 months ago · accessnewswire.com
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update- Cash burn of $3.8 million in Q2 remains in line with projected quarterly range - Cash and investments are sufficient to fund operations through Q3'2026 at current cash burn rate - Commercial readine...
